Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2011 (2011), Article ID 219049, 8 pages
http://dx.doi.org/10.1155/2011/219049
Review Article

Repeated Intrathecal Triamcinolone Acetonide Administration in Progressive Multiple Sclerosis: A Review

Department of Neurology, University of Rostock, Gehlsheimer Straße 20, 18147 Rostock, Germany

Received 1 December 2010; Revised 9 March 2011; Accepted 27 April 2011

Academic Editor: Ichiro Nakashima

Copyright © 2011 Mazen Abu-Mugheisib et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Multiple Sclerosis Society—About research, October 2010, http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/what-is-ms/download.aspx?id=22.
  2. B. C. Kieseier and H. P. Hartung, “Current disease-modifying therapies in multiple sclerosis,” Seminars in Neurology, vol. 23, no. 2, pp. 133–146, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, “Relapses and progression of disability in multiple sclerosis,” The New England Journal of Medicine, vol. 343, no. 20, pp. 1430–1438, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. C. Confavreux, S. Vukusic, and P. Adeleine, “Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process,” Brain, vol. 126, no. 4, pp. 770–782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö, “Axonal transection in the lesions of multiple sclerosis,” The New England Journal of Medicine, vol. 338, no. 5, pp. 278–285, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker, “Multiple sclerosis,” The New England Journal of Medicine, vol. 343, no. 13, pp. 938–952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Kornek and H. Lassmann, “Axonal pathology in multiple sclerosis: a historical note,” Brain Pathology, vol. 9, no. 4, pp. 651–656, 1999. View at Google Scholar · View at Scopus
  8. G. Filippini, F. Brusaferri, W. A. Sibley et al., “Corticosteroids or ACTH for acute exacerbations in multiple sclerosis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD001331, 2000. View at Google Scholar · View at Scopus
  9. D. M. Miller, B. Weinstock-Guttman, F. Bethoux et al., “A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations,” Multiple Sclerosis, vol. 6, no. 4, pp. 267–273, 2000. View at Google Scholar · View at Scopus
  10. R. Zivadinov, R. A. Rudick, R. De Masi et al., “Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS,” Neurology, vol. 57, no. 7, pp. 1239–1247, 2001. View at Google Scholar · View at Scopus
  11. N. D. Richert, J. L. Ostuni, C. N. Bash, T. P. Leist, H. F. McFarland, and J. A. Frank, “Interferon beta-1 b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis,” Multiple Sclerosis, vol. 7, no. 1, pp. 49–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. P. B. Andersson and D. E. Goodkin, “Glucocorticosteroid therapy for multiple sclerosis: a critical review,” Journal of the Neurological Sciences, vol. 160, no. 1, pp. 16–25, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. E. M. Martínez-Cáceres, M. A. Barrau, L. Brieva, C. Espejo, N. Barberà, and X. Montalban, “Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects,” Clinical and Experimental Immunology, vol. 127, no. 1, pp. 165–171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Cazzato, T. Mesiano, R. Antonello et al., “Double-blind, placebocontrolled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis,” European Neurology, vol. 35, no. 4, pp. 193–198, 1995. View at Google Scholar · View at Scopus
  15. C. Pozzilli, F. Marinelli, S. Romano, and F. Bagnato, “Corticosteroids treatment,” Journal of the Neurological Sciences, vol. 223, no. 1, pp. 47–51, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. L. Oliveri, G. Sibilia, P. Valentino, C. Russo, N. Romeo, and A. Quattrone, “Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis,” Acta Neurologica Scandinavica, vol. 97, no. 6, pp. 366–369, 1998. View at Google Scholar · View at Scopus
  17. D. S. Goodin, E. M. Frohman, G. P. Garmany Jr. et al., “Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines,” Neurology, vol. 58, no. 2, pp. 169–178, 2002. View at Google Scholar
  18. R. Heun, U. Sliwka, H. Ruttinger, and K. Schimrigk, “Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study,” Journal of Neurology, vol. 239, no. 1, pp. 31–35, 1992. View at Google Scholar · View at Scopus
  19. D. A. Nelson and W. M. Landau, “Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 70, no. 4, pp. 433–443, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Rohrbach, L. Kappos, D. Städt et al., “Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: a double-blind controlled trial,” Neurology, vol. 38, supplement 1, p. 256, 1988. View at Google Scholar
  21. H. A. Wilkinson, “Intrathecal Depo-Medrol: a literature review,” Clinical Journal of Pain, vol. 8, no. 1, pp. 49–56, 1992. View at Google Scholar
  22. G. Martino, “How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders,” Lancet Neurology, vol. 3, no. 6, pp. 372–378, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. G. F. Kamen and G. L. Erdman, “Subdural administration of hydrocortisone in multiple sclerosis: effect of ACTH,” Journal of the American Geriatrics Society, vol. 1, no. 11, pp. 794–804, 1953. View at Google Scholar
  24. G. J. Boines, “Remissions in multiple sclerosis following intrathecal methylprednisolone acetate,” Delaware Medical Journal, vol. 33, pp. 231–235, 1961. View at Google Scholar
  25. G. J. Boines, “Predictable remissions in multiple sclerosis,” Delaware Medical Journal, vol. 35, pp. 200–202, 1963. View at Google Scholar
  26. C. Van Buskirk, A. L. Poffenbarger, L. F. Capriles et al., “Treatment of multiple sclerosis with intrathecal steroids,” Neurology, vol. 14, pp. 595–597, 1964. View at Google Scholar
  27. N. P. Goldstein, W. F. McGuckin, B. F. McKenzie, and V. R. Mattox, “Experimental intrathecal administration of methylprednisolone acetate in multiple sclerosis,” Transactions of the American Neurological Association, vol. 95, pp. 243–244, 1970. View at Google Scholar
  28. D. A. Nelson, T. S. Vates, and R. B. Thomas, “Complications from intrathecal steroid therapy in patients with multiple sclerosis,” Acta Neurologica Scandinavica, vol. 49, no. 2, pp. 176–188, 1973. View at Google Scholar
  29. E. K. L. Rohrbach, D. Städt, A. Hennes et al., “Effects, side-effects and pharmacokinetics of intrathecal vs. oral corticosteroids in spinal symptoms of multiple sclerosis: results of a double-blind controlled trial,” Journal of Neurology, vol. 235, pp. 40–41, 1988. View at Google Scholar
  30. N. P. Goldstein, B. F. McKenzie, and W. F. McGuckin, “Changes in cerebrospinal fluid of patients with multiple sclerosis after treatment with intrathecal methylprednisolone acetate: a preliminary report,” Proceedings of the Staff Meetings. Mayo Clinic, vol. 37, pp. 657–668, 1962. View at Google Scholar
  31. T. Müller, “Role of intraspinal steroid application in patients with multiple sclerosis,” Expert Review of Neurotherapeutics, vol. 9, no. 9, pp. 1279–1287, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. D. A. Nelson, “Arachnoiditis from intrathecally given corticosteroids in the treatment of multiple sclerosis,” Archives of Neurology, vol. 33, no. 5, p. 373, 1976. View at Google Scholar
  33. J. H. Dougherty and R. A. Fraser, “Complications following intraspinal injections of steroids,” Journal of Neurosurgery, vol. 48, no. 6, pp. 1023–1025, 1978. View at Google Scholar
  34. J. L. Bernat, C. H. Sadowsky, and F. M. Vincent, “Sclerosing spinal pachymeningitis. A complication of intrathecal administration of Depo-Medrol for multiple sclerosis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 39, no. 11, pp. 1124–1128, 1976. View at Google Scholar
  35. V. M. Rivera, “Safety of intrathecal steroids in multiple sclerosis,” Archives of Neurology, vol. 46, no. 7, pp. 718–719, 1989. View at Google Scholar
  36. N. Kotani, T. Kushikata, H. Hashimoto et al., “Intrathecal methylprednisolone for intractable postherpetic neuralgia,” The New England Journal of Medicine, vol. 343, no. 21, pp. 1514–1519, 2000. View at Publisher · View at Google Scholar · View at PubMed
  37. V. Hoffmann, S. Schimrigk, S. Islamova et al., “Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients,” Journal of the Neurological Sciences, vol. 211, no. 1-2, pp. 81–84, 2003. View at Publisher · View at Google Scholar
  38. K. Hellwig, F. J. Stein, H. Przuntek, and T. Müller, “Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms,” BMC Neurology, vol. 4, p. 18, 2004. View at Publisher · View at Google Scholar · View at PubMed
  39. V. Hoffmann, W. Kuhn, S. Schimrigk et al., “Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients,” European Journal of Neurology, vol. 13, no. 1, pp. 72–76, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. K. Hellwig, S. Schimrigk, C. Lukas et al., “Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients,” Clinical Neuropharmacology, vol. 29, no. 5, pp. 286–291, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. H. J. Braune and G. Huffmann, “A prospective double-blind clinical trial, comparing the sharp Quincke needle (22G) with an “atraumatic” needle (22G) in the induction of post-lumbar puncture headache,” Acta Neurologica Scandinavica, vol. 86, no. 1, pp. 50–54, 1992. View at Google Scholar
  42. G. Comi, L. Leocani, S. Medaglini et al., “Evoked potentials in diagnosis and monitoring of multiple sclerosis,” Electroencephalography and Clinical Neurophysiology Supplement, vol. 49, pp. 13–18, 1999. View at Google Scholar
  43. P. A. Carbaat and H. Van Crevel, “Lumbar puncture headache: controlled study on the preventive effect of 24 hours' bed rest,” The Lancet, vol. 2, no. 8256, pp. 1133–1135, 1981. View at Google Scholar
  44. V. I. Leussink, S. Jung, U. Merschdorf, K. V. Toyka, and R. Gold, “High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes,” Archives of Neurology, vol. 58, no. 1, pp. 91–97, 2001. View at Google Scholar
  45. P. J. Jongen, S. Floris, W. H. Doesburg, W. A. Lemmens, O. R. Hommes, and K. J. Lamers, “Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis,” Multiple Sclerosis, vol. 4, no. 3, pp. 108–110, 1998. View at Google Scholar
  46. C. Malmeström, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke, “Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS,” Neurology, vol. 61, no. 12, pp. 1720–1725, 2003. View at Google Scholar
  47. F. Michetti, A. Massaro, and M. Murazio, “The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients,” Neuroscience Letters, vol. 11, no. 2, pp. 171–175, 1979. View at Publisher · View at Google Scholar
  48. A. R. Massaro, F. Michetti, A. Laudisio, and P. Bergonzi, “Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase,” The Italian Journal of Neurological Sciences, vol. 6, no. 1, pp. 53–56, 1985. View at Publisher · View at Google Scholar
  49. K. J. B. Lamers, B. G. van Engelen, F. J. Gabreels, O. R. Hommes, G. F. Borm, and R. A. Wevers, “Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders,” Acta Neurologica Scandinavica, vol. 92, no. 3, pp. 247–251, 1995. View at Google Scholar
  50. R. C. Melcangi, I. Cavarretta, V. Magnaghi, E. Ciusani, and A. Salmaggi, “Corticosteroids protect oligodendrocytes from cytokine-induced cell death,” NeuroReport, vol. 11, no. 18, pp. 3969–3972, 2000. View at Google Scholar
  51. F. J. Jiménez-Jiménez, J. M. Zurdo, A. Hernanz et al., “Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis,” Acta Neurologica Scandinavica, vol. 106, no. 6, pp. 351–354, 2002. View at Publisher · View at Google Scholar
  52. A. Martínez-Yélamos, A. Saiz, J. Bas, J. J. Hernandez, F. Graus, and T. Arbizu, “Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis,” Neuroscience Letters, vol. 363, no. 1, pp. 14–17, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. D. E. Goodkin, R. P. Kinkel, B. Weinstock-Guttman et al., “A phase II study of i.v methylprednisolone in secondary-progressive multiple sclerosis,” Neurology, vol. 51, no. 1, pp. 239–245, 1998. View at Google Scholar
  54. B. F. Martinelli, M. Rovaris, R. Capra, and G. Comi, “Mitoxantrone for multiple sclerosis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD002127, 2005. View at Google Scholar
  55. S. M. Leary and A. J. Thompson, “Primary progressive multiple sclerosis: current and future treatment options,” CNS Drugs, vol. 19, no. 5, pp. 369–376, 2005. View at Publisher · View at Google Scholar
  56. S. Goffette, V. Van Pesch, J. L. Vanoverschelde, E. Morandini, and C. J. M. Sindic, “Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone,” Journal of Neurology, vol. 252, no. 10, pp. 1217–1222, 2005. View at Publisher · View at Google Scholar · View at PubMed
  57. H. Krapf, S. P. Morrissey, O. Zenker, T. Zwingers, R. Gonsette, and H. P. Hartung, “Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial,” Neurology, vol. 65, no. 5, pp. 690–695, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. S. A. Rizvi, H. Zwibel, and E. J. Fox, “Mitoxantrone for multiple sclerosis in clinical practice,” Neurology, vol. 63, no. 12, supplement 6, pp. S25–S27, 2004. View at Google Scholar · View at Scopus
  59. M. Debouverie, N. Vandenberghe, S. P. Morrissey et al., “Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 4, pp. 407–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. V. C. Zingler, M. Strupp, K. Jahn et al., “The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients,” Der Nervenarzt, vol. 76, no. 6, pp. 740–747, 2005. View at Google Scholar
  61. E. L. Hoogervorst, C. H. Polman, and F. Barkhof, “Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone,” Multiple Sclerosis, vol. 8, no. 5, pp. 415–419, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Huston and R. Peterson, “Withholding proven treatment in clinical research,” The New England Journal of Medicine, vol. 345, no. 12, pp. 912–914, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus